Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,956,216
  • Shares Outstanding, K 637,219
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 36-Month Beta 1.21
  • Price/Sales 4.89
  • Price/Cash Flow 10.33
  • Price/Book 9.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 3.48
  • Number of Estimates 10
  • High Estimate 3.73
  • Low Estimate 3.04
  • Prior Year 3.47
  • Growth Rate Est. (year over year) +0.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.65 +4.84%
on 01/30/19
204.33 -7.83%
on 01/18/19
-11.04 (-5.54%)
since 01/15/19
3-Month
178.29 +5.64%
on 12/24/18
208.99 -9.88%
on 11/30/18
-4.11 (-2.14%)
since 11/15/18
52-Week
163.31 +15.33%
on 04/02/18
210.19 -10.40%
on 09/27/18
+4.74 (+2.58%)
since 02/15/18

Most Recent Stories

More News
U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor

Today the European Patent Office invalidated Immunex's European patent claiming antibodies that target human IL-4 receptors (IL-4R)

REGN : 423.97 (+2.17%)
AMGN : 188.34 (+0.89%)
HOOKIPA Appoints Michael A. Kelly as Independent Director

HOOKIPA Pharma Inc. ("HOOKIPA"), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced...

AMGN : 188.34 (+0.89%)
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

IBB : 112.04 (+1.65%)
FBT : 147.15 (+1.57%)
BBH : 129.21 (+1.20%)
GILD : 67.59 (+1.84%)
AMGN : 188.34 (+0.89%)
BIIB : 332.87 (+2.51%)
ALXN : 129.42 (+2.77%)
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

IBB : 112.04 (+1.65%)
FBT : 147.15 (+1.57%)
BBH : 129.21 (+1.20%)
GILD : 67.59 (+1.84%)
AMGN : 188.34 (+0.89%)
BIIB : 332.87 (+2.51%)
ALXN : 129.42 (+2.77%)
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report

Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.

LLY : 122.48 (+1.43%)
NVS : 89.88 (+0.97%)
TEVA : 17.98 (+4.05%)
AMGN : 188.34 (+0.89%)
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration

Abilita Bio, Inc. announced today that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will...

AMGN : 188.34 (+0.89%)
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

MRK : 79.81 (+1.10%)
INCY : 84.15 (+0.88%)
AMGN : 188.34 (+0.89%)
GSK : 41.24 (+0.93%)
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma...

BLUE : 137.03 (+2.04%)
ABBV : 80.85 (+0.41%)
AMGN : 188.34 (+0.89%)
BMY : 51.67 (+1.65%)
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

CI : 197.87 (+2.94%)
REGN : 423.97 (+2.17%)
AMGN : 188.34 (+0.89%)
SNY : 42.55 (+2.38%)
Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View

Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.

LGND : 120.86 (-0.02%)
NVS : 89.88 (+0.97%)
AMGN : 188.34 (+0.89%)
RTRX : 21.56 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 190.92
1st Resistance Point 189.63
Last Price 188.34
1st Support Level 186.52
2nd Support Level 184.70

See More

52-Week High 210.19
Fibonacci 61.8% 192.28
Last Price 188.34
Fibonacci 50% 186.75
Fibonacci 38.2% 181.22
52-Week Low 163.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar